Answers are grounded in this paper and cite their sources.
This systematic review and meta-analysis evaluated the effects of branched-chain amino acid (BCAA) supplementation on serum albumin levels in patients with cancer and explored the dose- and duration-related patterns of the observed effects. Parallel and crossover clinical trials evaluating BCAA supplementation on serum albumin levels in patients with any cancer type were included. Observational studies, reviews, editorials, gray literature, animal studies, studies without control groups, non-English publications, trials combining BCAAs with other interventions, and studies reporting only in vitro or gene expression outcomes were excluded. PubMed, Web of Science, Scopus, and Google Scholar were searched from inception to July 2025. Risk of bias was assessed using the Revised Cochrane Risk of Bias Tool (RoB 2). Random-effects meta-analyses using the DerSimonian–Laird method were performed to calculate weighted mean differences (WMDs) with 95% confidence intervals (CIs). Dose–response and subgroup analyses were conducted according to the route of administration. Twenty-two controlled clinical trials involving 1,188 participants were included, with intervention durations ranging from 3 to 372 days. Oral BCAA supplementation significantly increased serum albumin levels compared with controls (WMD: 0.16 g/dL; 95% CI: 0.04–0.29; P = 0.009). Dose–response analysis indicated greater improvements with oral doses of 9.38–12.52 g/day and intervention durations longer than 292 days. Parenteral BCAA supplementation showed no significant effect. Despite heterogeneity and risk of bias across studies, oral BCAA supplementation may modestly improve serum albumin levels in patients with cancer, particularly at higher doses and with longer intervention durations.
No takes yet. Share an insight, caveat, or question.
Rezaee-Moghadam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: